Bevacizumab in the treatment of uterine cervix carcinoma

Simple item page
dc.contributor.authorDvořák Josefcs
dc.contributor.authorRichter Igorcs
dc.contributor.authorProkš Jancs
dc.contributor.authorRozsypalová Anetacs
dc.contributor.authorGrimová Janacs
dc.date.accessioned2021-01-14T18:07:52Z
dc.date.available04-55-2021en
dc.date.available2021-01-14T18:07:52Z
dc.date.issued2021cs
dc.date.updated04-57-2021en
dc.format.extent3cs
dc.identifier.issn2464-7195cs
dc.identifier.urihttps://dspace.tul.cz/handle/15240/158730
dc.language.isoczecs
dc.relation.ispartofOnkologická Revueen
dc.relation.ispartofseries0cs
dc.relation.urihttps://onkologickarevue.cz/en/bevacizumab-in-the-treatment-of-uterine-cervix-carcinomacs
dc.subjectuterine cervix carcinomacs
dc.subjectsystemic treatmentcs
dc.subjectchemotherapycs
dc.subjectbevacizumabcs
dc.titleBevacizumab in the treatment of uterine cervix carcinomaen
dc.titleBevacizumab v léčbě pacientek s karcinomem děložního hrdlacs
local.citation.epage51-53cs
local.citation.spage51-53cs
local.identifier.publikace8057
local.relation.issue7cs
Files
Collections